PRIME status for Ignyta’s entrectinib
admin 18th October 2017 Uncategorised 0European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.
More: PRIME status for Ignyta’s entrectinib
Source: News